These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 29527631)

  • 1. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
    Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    Martín-Liberal J; López-Pousa A; Broto JM; Cubedo R; Gallego O; Brendel E; Tirado OM; del Muro XG
    Invest New Drugs; 2014 Apr; 32(2):287-94. PubMed ID: 23801301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
    Leyvraz S; Bacchi M; Cerny T; Lissoni A; Sessa C; Bressoud A; Hermann R
    Ann Oncol; 1998 Aug; 9(8):877-84. PubMed ID: 9789611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
    Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of 5-fluorouracil, adriamycin, ifosfamide and cisplatin in metastatic adult soft tissue sarcoma: results of a phase II study.
    Jäger E; Klein O; Wächter B; Bernhard H; Dippold W; Meyer zum Büschenfelde KH; Knuth A
    Oncology; 1996; 53(1):58-63. PubMed ID: 8570133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
    Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
    Schütte J; Mouridsen HT; Steward W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S204-9. PubMed ID: 8453699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
    J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
    Schütte J; Mouridsen HT; Stewart W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
    Eur J Cancer; 1990; 26(5):558-61. PubMed ID: 2144740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
    Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
    Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS).
    Buesa JM; López-Pousa A; Martín J; Antón A; García del Muro J; Bellmunt J; Arranz F; Valentí V; Escudero P; Menéndez D; Casado A; Poveda A
    Ann Oncol; 1998 Aug; 9(8):871-6. PubMed ID: 9789610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
    Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S
    Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
    Budd GT; Metch B; Weiss SA; Weick JK; Fabian C; Stephens RL; Balcerzak SP
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S213-6. PubMed ID: 8453701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules.
    Serrone L; Zeuli M; Papaldo P; Nardoni C; Pacetti U; Cognetti F
    Onkologie; 2001 Oct; 24(5):465-8. PubMed ID: 11694773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series.
    ElNaggar AC; Hays JL; Chen JL
    PLoS One; 2016; 11(6):e0156985. PubMed ID: 27295141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.